KARAAĞAÇ, M. Et Al. 2020. Irinotecan and Ifosfamide Combination is an Effective and Safe Option in Patients with Refractory Small Cell Lung Cancer: A Retrospective Cross-Sectional Study. EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY , vol.4, no.2 , 172-176.

KARAAĞAÇ, M., ARTAÇ, M., SEZGİN GÖKSU, S., Eryilmaz, M. K., COŞKUN, H. Ş., & Bozcuk, H., (2020). Irinotecan and Ifosfamide Combination is an Effective and Safe Option in Patients with Refractory Small Cell Lung Cancer: A Retrospective Cross-Sectional Study. EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY , vol.4, no.2, 172-176.

KARAAĞAÇ, MUSTAFA Et Al. "Irinotecan and Ifosfamide Combination is an Effective and Safe Option in Patients with Refractory Small Cell Lung Cancer: A Retrospective Cross-Sectional Study," EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY , vol.4, no.2, 172-176, 2020

KARAAĞAÇ, MUSTAFA Et Al. "Irinotecan and Ifosfamide Combination is an Effective and Safe Option in Patients with Refractory Small Cell Lung Cancer: A Retrospective Cross-Sectional Study." EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY , vol.4, no.2, pp.172-176, 2020

KARAAĞAÇ, M. Et Al. (2020) . "Irinotecan and Ifosfamide Combination is an Effective and Safe Option in Patients with Refractory Small Cell Lung Cancer: A Retrospective Cross-Sectional Study." EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY , vol.4, no.2, pp.172-176.

@article{article, author={MUSTAFA KARAAĞAÇ Et Al. }, title={Irinotecan and Ifosfamide Combination is an Effective and Safe Option in Patients with Refractory Small Cell Lung Cancer: A Retrospective Cross-Sectional Study}, journal={EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY}, year=2020, pages={172-176} }